Skip to main content
. 2022 Jul 16;7:100155. doi: 10.1016/j.prdoa.2022.100155

Fig. 4.

Fig. 4

Representative [18F]-APN-1607 (or [18F]PM-PBB3) PET images superimposed on T1 MRI in PSP patients versus PD and controls. Compared to PD and HC, patients with PSP display heightened tracer binding in the midbrain, basal ganglia, subcortical nuclei, and brainstem. The colour scale represents standardized uptake value ratio (SUVR) with cerebellar cortex as the reference regions. PSP-RS = progressive supranuclear palsy-Richardson’s syndrome, PD = Parkinson’s disease, HC = healthy controls. Figure modified from Li L, Liu FT, Li M, Lu JY, Sun YM, Liang X, Bao W, Chen QS, Li XY, Zhou XY, Guan Y, Wu JJ, Yen TC, Jang MK, Luo JF, Wang J, Zuo C; Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI). Clinical Utility of 18F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. Mov Disord. 2021 Oct;36(10):2314–2323. https://doi.org/10.1002/mds.28672. Epub 2021 Jun 5. PMID: 34089275.